CY1114367T1 - Δισκιο και κοκκοποιημενη σκονη που περιεχει 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδιο - Google Patents

Δισκιο και κοκκοποιημενη σκονη που περιεχει 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδιο

Info

Publication number
CY1114367T1
CY1114367T1 CY20131100783T CY131100783T CY1114367T1 CY 1114367 T1 CY1114367 T1 CY 1114367T1 CY 20131100783 T CY20131100783 T CY 20131100783T CY 131100783 T CY131100783 T CY 131100783T CY 1114367 T1 CY1114367 T1 CY 1114367T1
Authority
CY
Cyprus
Prior art keywords
fluoro
hydroxy
tablet
pyrazinocarcoamide
powder containing
Prior art date
Application number
CY20131100783T
Other languages
English (en)
Inventor
Sahoe Kakuda
Setsuko Nishimura
Takafumi Hirota
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of CY1114367T1 publication Critical patent/CY1114367T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτεται ένα χρήσιμο δισκίο το οποίο περιέχει μία υψηλή ποσότητα 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδίου ή άλατος αυτού, έχει μέγεθος το οποίο είναι εύκολο για κατάποση, έχει ανώτερα χαρακτηριστικά απελευθέρωσης και έχει σκληρότητα η οποία μπορεί να υποστεί επικάλυψη με φιλμ, συσκευασία και μεταφορά.
CY20131100783T 2009-03-13 2013-09-10 Δισκιο και κοκκοποιημενη σκονη που περιεχει 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδιο CY1114367T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009061837 2009-03-13
EP10750921.8A EP2407166B1 (en) 2009-03-13 2010-03-12 Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide

Publications (1)

Publication Number Publication Date
CY1114367T1 true CY1114367T1 (el) 2016-08-31

Family

ID=42728455

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100783T CY1114367T1 (el) 2009-03-13 2013-09-10 Δισκιο και κοκκοποιημενη σκονη που περιεχει 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδιο

Country Status (23)

Country Link
US (1) US8513261B2 (el)
EP (1) EP2407166B1 (el)
JP (1) JP5583659B2 (el)
KR (1) KR101665395B1 (el)
CN (1) CN102348458B (el)
AU (1) AU2010222029B2 (el)
BR (1) BRPI1013187A2 (el)
CA (1) CA2755274C (el)
CY (1) CY1114367T1 (el)
DK (1) DK2407166T3 (el)
ES (1) ES2429689T3 (el)
HR (1) HRP20130858T1 (el)
IL (1) IL215085A (el)
MX (1) MX2011009440A (el)
NZ (1) NZ595071A (el)
PL (1) PL2407166T3 (el)
PT (1) PT2407166E (el)
RU (1) RU2527766C2 (el)
SG (1) SG174291A1 (el)
SI (1) SI2407166T1 (el)
TW (1) TWI463999B (el)
WO (1) WO2010104170A1 (el)
ZA (1) ZA201106660B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161429A (en) 2010-09-30 2017-04-14 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
SG188662A1 (en) 2010-09-30 2013-05-31 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CN102977039B (zh) * 2012-12-12 2014-09-10 山东齐都药业有限公司 6-氟-3-羟基-2-吡嗪甲酰胺α晶型及其制备方法
CN104271134B (zh) * 2013-01-15 2016-06-29 富士胶片株式会社 含有5-羟基-1h-咪唑-4-甲酰胺的片剂
CN104288154B (zh) * 2014-09-29 2017-01-18 成都新恒创药业有限公司 一种含有不同粒径范围的法匹拉韦药物组合物
WO2016120301A1 (en) 2015-01-28 2016-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of ebola virus disease
CN105687152B (zh) * 2016-03-22 2020-04-07 山东齐都药业有限公司 一种法匹拉韦快速释放药物制剂及制备方法
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
CN109125271A (zh) * 2017-06-27 2019-01-04 北京阜康仁生物制药科技有限公司 一种使用流化床制备含有法匹拉韦中间体颗粒的方法
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
US20230127703A1 (en) 2020-03-30 2023-04-27 Fujifilm Toyama Chemical Co., Ltd. Therapeutic agent for coronavirus infection
RU2731932C1 (ru) * 2020-05-07 2020-09-09 Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") Противо-COVID-19 (SARS-CoV-2) вирусная фармацевтическая композиция
RU2764444C1 (ru) * 2020-09-07 2022-01-17 Общество с ограниченной ответственностью "Кромис", (ООО "Кромис") Противо-SARS-CoV-2 вирусная фармацевтическая композиция и ее применение
RU2740657C1 (ru) * 2020-05-15 2021-01-19 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная композиция
JP2023527798A (ja) * 2020-05-23 2023-06-30 リミテッド・ライアビリティ・カンパニー“クロミス” ＣＯＶＩＤ－１９（ＳＡＲＳ－ＣｏＶ－２）を含むＲＮＡウイルス感染を治療するための方法
RU2751108C1 (ru) * 2020-06-15 2021-07-08 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная композиция
WO2021253681A1 (zh) * 2020-06-19 2021-12-23 浙江华海药业股份有限公司 一种法匹拉韦组合物及其制备方法
HUP2000379A1 (hu) * 2020-11-17 2022-05-28 Meditop Gyogyszeripari Kft Favipiravir tartalmú gyógyszerkészítmény, ennek elõállítása és alkalmazása
EP4321163A1 (en) 2021-04-08 2024-02-14 FUJIFILM Toyama Chemical Co., Ltd. Therapeutic agent for coronavirus infection
JPWO2023008530A1 (el) 2021-07-30 2023-02-02

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
JPH09208468A (ja) * 1996-02-02 1997-08-12 Dainippon Pharmaceut Co Ltd ｐ−クロロ−Ｎ−（２−モルホリノエチル）ベンズアミドを含有する錠剤
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
NZ509748A (en) * 1998-08-20 2003-01-31 Toyama Chemical Co Ltd Nitrogenous heterocyclic carboxamide derivatives or salts useful as antiviral agents
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
IT1311907B1 (it) * 1999-04-06 2002-03-20 Zambon Spa Compresse deglutibili ad alto contenuto di n-acetilcisteina.
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
CA2423329A1 (en) 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
JP4370050B2 (ja) 2000-12-04 2009-11-25 大正製薬株式会社 クラリスロマイシン錠剤およびその製造法
RU2297414C2 (ru) * 2001-02-14 2007-04-20 Тояма Кемикал Ко., Лтд. Производные пиразина или их соли, фармацевтическая композиция, содержащая данные соединения, и промежуточные соединения для их получения
RU2190407C1 (ru) * 2001-08-23 2002-10-10 Нестерук Владимир Викторович Способ получения противовирусного средства
KR20030041531A (ko) * 2001-11-20 2003-05-27 김영식 건설현장용 안전시스템
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
WO2005120463A1 (en) 2004-06-09 2005-12-22 Ranbaxy Laboratories Limited Rapidly disintegrating tablets of risperidone
JP4999297B2 (ja) * 2005-08-10 2012-08-15 高田製薬株式会社 高含量塩酸テルビナフィン小型錠剤
JP5021210B2 (ja) 2006-01-16 2012-09-05 エスエス製薬株式会社 圧縮成型製剤
KR20090022616A (ko) * 2007-08-31 2009-03-04 한올제약주식회사 베실산클로피도그렐 함유 경구투여용 약제
WO2010095041A2 (en) * 2009-02-18 2010-08-26 Excrx (Singapore) Pte.Ltd. Compositions, methods, and kits for treating influenza viral infections

Also Published As

Publication number Publication date
KR20110126699A (ko) 2011-11-23
KR101665395B1 (ko) 2016-10-12
CA2755274C (en) 2017-02-28
EP2407166A1 (en) 2012-01-18
SI2407166T1 (sl) 2013-12-31
AU2010222029A1 (en) 2011-09-29
NZ595071A (en) 2013-01-25
SG174291A1 (en) 2011-10-28
ZA201106660B (en) 2012-11-28
IL215085A0 (en) 2011-11-30
DK2407166T3 (da) 2013-10-07
EP2407166A4 (en) 2012-07-18
PL2407166T3 (pl) 2014-01-31
CA2755274A1 (en) 2010-09-16
US8513261B2 (en) 2013-08-20
IL215085A (en) 2016-08-31
US20120010221A1 (en) 2012-01-12
PT2407166E (pt) 2013-11-25
CN102348458B (zh) 2013-11-06
EP2407166B1 (en) 2013-08-21
BRPI1013187A2 (pt) 2016-04-12
HRP20130858T1 (hr) 2013-10-11
MX2011009440A (es) 2011-11-04
CN102348458A (zh) 2012-02-08
RU2527766C2 (ru) 2014-09-10
TW201036649A (en) 2010-10-16
ES2429689T3 (es) 2013-11-15
JP5583659B2 (ja) 2014-09-03
RU2011141496A (ru) 2013-04-20
TWI463999B (zh) 2014-12-11
WO2010104170A1 (ja) 2010-09-16
JPWO2010104170A1 (ja) 2012-09-13
AU2010222029B2 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
CY1114367T1 (el) Δισκιο και κοκκοποιημενη σκονη που περιεχει 6-φθορο-3-υδροξυ-2-πυραζινοκαρβοξαμιδιο
CY1120674T1 (el) Καψουλα ατομικης μεριδας με κωδικο αναγνωρισης
CY1122544T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη και κυτιο αντισυλληψης
CY1124843T1 (el) Κρυσταλλικες στερεες μορφες της 6-κaρβοξυ-2-(3,5-διχλωρο-φαινυλο)-βενζοξαζολης
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
MX2017007629A (es) Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
CL2017000753A1 (es) Método para producir una biomasa granular que contiene una sustancia valiosa sensible a la oxidación
CR20130104A (es) Compuestos y composiciones novedosos para la inhibicion de nampt
CR8647A (es) Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen
HN2011003195A (es) Modulares de gpr 119
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
EA201001710A3 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CO2017012278A2 (es) Cartucho biodegradable para escopetas
CY1123895T1 (el) Φαρμακευτικα σκευασματα λοραταδινης για εγκλεισμο σε καψακια και συνδυασμοι αυτων
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2
FR2945921B1 (fr) Recipient cosmetique
AR083752A1 (es) Envoltorio de esterilizacion biodegradable
EA201590250A1 (ru) Производные карбамат/мочевины
TR200908237A2 (tr) Kalsiyum ve D vitamini içeren farmasötik bileşimler.
CY1119159T1 (el) Δισκιο το οποιο περιεχει 5-υδροξυ-1η-ιμιδαζολο-4-καρβοξαμιδiο
CL2016003155A1 (es) Composiciones de cuidado bucal
CO6771413A2 (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones framacéuticas